SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.03-2.2%9:41 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: A.J. Mullen who wrote (7726)1/15/2003 11:53:50 AM
From: tuck  Read Replies (1) of 52153
 
Ashley,

the ban appears to only be on retroviruses. If memory serves (it does not always serve well) the first death from gene therapy in Philadelphia involved a retrovirus. Thereafter, a lot of gene therapists began using different vectors, such as adenoviruses and their ilk. A retrovirus contains RNA as its genetic material, which is why Vical's approach would not be likely to run into this problem, at least not by the same mechanism.

I'm obviously no expert, and welcome corrections and clarifications.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News